Digest Réseau Comment ça marche
Réseau
/
Sociétés
AC
Non vérifié

AC Immune SA

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

31 communiqués de presse

Voir tous les communiqués de presse
11/08/2026
Biotechnologie
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
05/08/2026
Biotechnologie
Management/Organisation d'Entreprise
AC Immune First Half 2026 Financial and Corporate Update
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
07/07/2026
Biotechnologie
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
30/06/2026
Biotechnologie
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
11/06/2026
Biotechnologie
Finance
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
Press Release cover image
22/05/2026
Biotechnologie
Médecine Santé Bien-être
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
12/05/2026
Biotechnologie
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
30/04/2026
Biotechnologie
Management/Organisation d'Entreprise
AC Immune First Quarter 2026 Financial and Corporate Updates
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
30/04/2026
Biotechnologie
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0
07/04/2026
Biotechnologie
Finance
Management/Organisation d'Entreprise
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
Source
AC Immune SA
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0